Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) have earned an average rating of “Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a strong buy recommendation to the company.

A number of equities analysts recently commented on the company. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, December 1st. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded Inhibikase Therapeutics to a “sell” rating in a research note on Saturday. HC Wainwright raised Inhibikase Therapeutics to a “strong-buy” rating in a report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Wednesday, October 8th.

Inhibikase Therapeutics Stock Performance

Shares of IKT opened at $1.96 on Friday. The stock’s fifty day moving average price is $1.57. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $3.49. The firm has a market capitalization of $147.35 million, a P/E ratio of -5.03 and a beta of 0.88.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.13) EPS for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.